A phase II study using GPC3 peptide vaccines as adjuvant maintenance therapy in 35 patients with HCC showed efficacy in delaying HCC recurrence at the 1-year, however, not at the 2-year mark [51]. The gene discussed is GPC3; the disease is hepatocellular carcinoma.